<DOC>
	<DOC>NCT02361294</DOC>
	<brief_summary>The study is designed to evaluate the role of platelets and immature platelets in the ethiopathology of deep venous thrombosis and pulmonary embolism.</brief_summary>
	<brief_title>Immature Plateletes in the Etiopathology of Deep Venous Thrombosis</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<criteria>Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The thrombembolism is idiopathic or caused by immobilisation. Control: Patients that present with a suspicion of deep venous thrombosis which is excluded by duplex sonography. therapy with glycoprotein IIb/IIIaantagonists within the last 10 days therapy with antiplatelet drugs (ASA, Clopidogrel, Ticagrelor, Prasugrel, Dipyridamol) preexisting anticoagulation number of platelets &lt; 100.000/µl anemia (hematocrit &lt; 35%, Hb &lt; 10 g/dl) age &gt; 80 y or &lt; 18 y renal insufficiency GFR &lt; 30 ml/min hepatic impairment with an increased risk for bleeding or coagulopathy, or liver cirrhosis (≥ Child Pugh B) intracranial or intracerebral bleeding within the last six months intraspinal or intracerebral vascular anomalies clinically relevant acute bleedings malign disease infections within the last 7 d hematological, rheumatologic and autoimmune diseases operations within the last six months transfusion of rec celll concentrates within the last six months transfusion of fresh frozen plasma or platelet concentrates within the last month preexisting medication with CYP 3A4 inhibitors and inductors, pglycoprotein inhibitors (AzolAntimycotis, HIV proteaseinhibitors) hypersensitivity/contraindications for Rivaroxaban pregnancy or lactation thrombophilia thrombocytopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>